-tetrahydropyridine (MPTP) btlirh trace cimoirnts of I-methyl-4-phenyl-4-propionoxy-piperidin (MPPP). On the hrisis of the striking parkinsonian features observed in orir patients, and udcliriot~ril prrthologic.rr1 dritcl fiom one previously reported case, it is proposed thcit this c.llemic.cil selectively damages cells in the substantia nigra.
I-Methyl-4-phenyl-l,2,5,6-tetrahydrop y r~d~n e (MPTP) IS a commerc~ally ava~l-able compound that IS sold as a chem~cal ~n t e r m e d~a t e (I). The b~olog~cal effects of t h~s substance seem not to have been systemat~cally Investigated in an~mals or in man. MPTP IS also a by-product In the synthes~s of I-methyl-4-phenyl-4-prop~o n o x y -p~p e r~d~n e (MPPP), a meperid~n e analog (2) Adm~xed w~t h varylng amounts of MPPP, MPTP was recently sold as a new "synthetic heroin" In a l~mited reglon of northern C a l~f o r n~a and used ~ntravenously by a number of add~c t e d ~n d~v~d u a l s who subsequently developed severe park~nson~sm. In t h~s report we descr~be four of these patlents, each of whom has been examlned and followed by one or more of us
MPTP MPPP
The patlent group cons~sted of one female and three males, whose ages ranged from 26 to 42 years Each patlent had a h~story of prevlous h e r o~n abuse (3 months to 14 years). Patlents I and 2 obta~ned a "new heroin" sample In San Jose, C a l~f o r n~a , on I July 1982; patlents 3 and 4 (brothers) rece~ved t h e m In Watsonv~lle, C a l~f o r n~a , about 3 weeks earher. Dosages ranged from 5 g over 4 days (cases I and 2) to 20 g over 5 to 8 days (cases 3 and 4). All patlents became symptomatic w~t h~n a week after start~ng to use the new drug. First symptoms included almost immediate visual hallucinations (one patient), jerking of limbs (two patients), and stiffness (one patient). Generalized slowing and d~fficulty in moving occurred within 4 to 14 days after the initial use of the substance. In at least one patient, symptoms continued to evolve over a period of 3 to 5 days after the drug was stopped.
Three of the four patients were hospitalized within 14 days to 6 weeks of first use of the drug. Examination in each revealed near total ~mmobility, marked generalized increase in tone, a complete inability to speak intellig~bly, a fixed stare, marked diminution of blinking, facial seborrhea, constant drooling, a positive glabellar tap test, and cogwheel rigid~ty in the upper extremities. One patient exhibited a "pill-rolling" tremor (5 to 6 cycles per second) at rest in the right hand. All patients exhibited a flexed posture typical of fully developed Parkinson's disease. The fourth patient (case 4) was seen as an outpatient 4 weeks after onset of symptoms. H e was able to walk but exhibited a shortstepped, slow, shuffling gait, "en bloc" turnlng, and generalized bradykinesia. In our examinat~on of him, he was otherwise similar to the other three patients.
Additional findings in these patients included apraxia of eyelid opening in three patients (3) and limitation of vertical gaze in two patients. Electroencephalograms were normal in three patients; a fourth exhibited intermittent bitemporal slowing. Results of cerebral computerlzed tomography were normal In the three patlents who underwent the procedure. Lumbar puncture revealed an elevated proteln In three of the four patlents (range 47 to 120 mgldl). Tests for WIIson's d~s e a s e were negatlve In all four patients. Complete t o x~c screens for acldlc, neutral, and baslc drugs In plasma and urlne ~n c l u d~n g phenoth~az~nes were negatlve In the two patlents tested (4). Heavy metal x r e e n s tn these two patlents were also negatlve.
All patlents responded to therapy wtth a c o m b~n a t~o n of L-dopa and carbldopa (S~nemet). A d d~t~o n of dopam~ne agonlst therapy (bromocr~pt~ne or I~surlde) provlded a d d~t~o n a l therapeut~c response In two patlents. F~v e months after onset, none of these patients have shown s~g n s of reml5slon. All contlnue to require substantla1 doses of these m e d~c a t~o n s , and one patlent 1s now experiencing dose-l~mrt~ng s~d e effects. One patient (case 3) had all m e d~c a t~o n s stopped 2 months after onset of symptoms for 5 days. D u r~n g t h~s perlod the patlent completely reverted to h~s o r~g~n a l state of complete ~m m o b~l i t y and r~g~d~t y , b e~n g able to move only h~s eyes. Swallowing was ~mpalred to the point that he req u~r e d Intravenous hydration untll his m e d~c a t~o n s could be effectively resumed.
Analyses of all drug samples were performed by uslng th~n-layer chromatography (TLC), gas chromatography (GC), and combined gas chromatography and mass spectrometry (GCIMS). Both MPTP and MPPP were Identified by means of GCIMS (Fig I) . Confirmatlon and quahtltatlon was performed w~t h reference mater~al obta~ned from Aldr~ch Chem~cal Company ( I ) and the Nat~onal Inst~tute of Mental Health (5). A sample of the powder whlch was injected by patlents I and 2 was obtalned from thelr res~dences T h~s w h~t e crystall~n e powder conta~ned 3 2 percent MPTP and 0.3 percent MPPP (by welght).
Three a d d~t~o n a l samples were obtained from the ~n d~v~d u a l who suppl~ed drugs to patlents 3 and 4. These samples were s a~d to contaln the same substance our patlents had been tak~ng when symptoms developed and add~tional amounts of "good hero~n" (presumably the target compound, MPPP) w h~c h had been added later to make ~t more salable. These brown granular samples also conta~ned MPTP at concentrations ranglng between 2 5 ahd 2.9 percent (by we~ght) They also conta~ned large amounts of MPPP (between 22 and 27 percent by weight). N o other drugs were detected In any of the samples analyzed.
A case reported by Davis et rrl (6) has great bear~ng on the patlent mater~al re-ported here. Their patient was a graduate student who produced his own drugs. For 4 to 6 months he had been synthesizing MPPP (using a reaction which produced MPTP as a by-product) and injecting it intravenously without problems. Apparently, after taking several "shortcuts" in synthesis and injecting the resulting product, he developed marked parkinsonism. After repeating the student's synthetic methods, it was concluded that he had injected a mixture of I-methyl-4-phenyl-4-hydroxypiperidine, MPPP, and MPTP (6).
The powders used by our patients were believed to be the products of a clandestine laboratory attempting to produce MPPP by the previously cited synthetic method (2) . In this synthesis the percentage of MPTP formed is dependent on reaction conditions (2, 6). More vigorous conditions result in a higher percentage of MPTP formed. Analysis of a sample taken from this illicit laboratory shortly after these cases were identified revealed virtually pure MPTP (7).
We suspect that MPTP is the offending agent in these patients for several reasons. First, MPTP was the major component in the material injected by patients 1 and 2. Second, MPTP was also present in almost identical concentrations in the material which patients 3 and 4 were said to have taken. Third, MPTP was likely to have been present in the substance injected by the previously reported student when he became symptomatic (6). Finally, it was known to be available locally in relatively pure form.
It seems less likely that MPPP is the offending agent since it was present in only trace amounts in the powder taken by two of our patients. Further, MPPP was probably added to the substance taken by patients 3 and 4 at a later time. Intravenous use of MPPP by the previously reported graduate student for a period of 5 to 6 months did not result in this syndrome (6). Last, MPPP bears a great similarity to the analgesic alphaprodine (Nisentil), differing only by the absence of a methyl group in the position 3. Although alphaprodine is used as an intravenous analgesic, we have been unable to find any reports of similar effects from the drug. However, for determination of the exact neurotoxicity of these substances, animal studies will be required.
Crucial to understanding of the biological effects of this compound are the neuropathological findings in the case reported by Davis at al. (6). Their patient died of a drug overdose 2 years after the onset of his parkinsonism. Destruction within the substantia nigra with neuromelanin pigment within microglial cells and a structure resembling a Lewy body were reported. We have reviewed this material (with Lysia S. Forno, M.D.) and confirmed the nerve cell degeneration in the substantia nigra. Moderately severe nerve cell loss was comparable in severity to that usually seen in idiopathic parkinsonism. There was abundant extraneuronal melanin pigment and a considerable astrocytic response with focal glial scarring. The changes were present throughout the compact zone of the substantia nigra but were more severe in the caudal portion. A single eosinophilic body, perhaps representing a Lewy body, was found. In contrast to cases of idiopathic parkinsonism the locus coeruleus and dorsal motor vagus nucleus were essentiallv normal.
It appears likely that similar cell damage has occurred in our patients. We base this opinion on the clinical similarity between our cases and the pathologically studied patient, and the fact that all of our patients continue to be symptomatic at five or more months after the initial insult. All continue to require the previously mentioned medications. The elevated spinal fluid protein seen in three of our patients [as well as the case reported by Davis et al. (6) ] is also suggestive of neuronal damage (rather than being a simple receptor blockade such as occurs with phenothiazines). The response to dopamine precursors and agonists in our patients would suggest that the striatum is at least partially spared, a situation analogous to Parkinson's disease.
Documenting the potential neurotoxicity of MPTP and possibly MPPP is important for several reasons. First, it should aid in the identification of the substance and management of future such cases should they occur. There may be additional attempts to manufacture meperidine analogs, and this substance may again appear io the illicit drug market. Second, this drug appears to be remarkably selective in its neurotoxic effects. Given the pathologically studied case, the relative purity of the clinical syndrome seen in our patients, and its remarkable clinical resemblance to Parkinson's disease, the drug may be of value in producing an animal model of Parkinson's disease. Finally, understanding of its mechanism of action might shed some light on the etiology of Parkinson's disease. An endogenous substance accumulating in the brain might have properties similar to these substances, thereby causing selective cell death in the substantia nigra with resulting parkinsonism.
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